• Explore /
  • Poster
  • / Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Abstract Poster

Authors

null

Franck Morschhauser

CHU Lille- Hopital Claude Huriez, Lille, France

Franck Morschhauser , Gilles A. Salles , Steven Le Gouill , John A. Radford , Pamela McKay , Guillaume Cartron , Patricia J. Pimentel , Maria Roche , Stephen J Blakemore , Alice McDonald , Natalie Warholic , Shelley Knight , Peter T.C. Ho , Vincent Ribrag

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT01897571

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS7582)

DOI

10.1200/JCO.2016.34.15_suppl.TPS7582

Abstract #

TPS7582

Poster Bd #

133a

Abstract Disclosures

Similar Posters

First Author: Kiyoshi Ando

First Author: Joanna S. Yi

First Author: Don A. Stevens

First Author: Marjorie Glass Zauderer